Cadrenal Therapeutics, Inc. — Investor Relations & Filings

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing novel anticoagulation therapeutics to address critical gaps in the treatment of cardiovascular diseases. The company's clinical-stage portfolio targets both chronic and acute care settings. Its lead candidate, tecarfarin, is an oral vitamin K antagonist (VKA) designed to provide more stable and predictable anticoagulation for high-risk patients, including those with end-stage kidney disease (ESKD) and atrial fibrillation or with implanted cardiac devices. The company is also advancing frunexian, a parenteral small-molecule Factor XIa inhibitor, for use in acute hospital settings such as complex cardiac surgeries. Cadrenal aims to improve standards of care by developing therapies with fewer bleeding complications for underserved patient populations.